Michael D Altman

This inventor holds 59 USPTO granted patents and 12 published patent applications, plus 3 CIPO patents and 49 EPO patents, primarily in Cancer Therapeutics (CPC class C07D). Top assignees: Merck Sharp + Dohme Corp., Merck Canada Inc., Merck Sharp & Dohme LLC. Active years: 2012-2026.

USPTO Granted Patents = 59 (Patent Applications = 12)

% Patents Active = 96.6

CIPO Patents = 3 (Patent Applications = 6)

EPO Patents = 49 (Patent Applications = 57)

Average Co-Inventor Count = 8.4

ph-index = 8

Forward Citations = 228(Granted Patents)

Forward Citations (Not Self Cited) = 149(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Cambridge, MA (US) (2012 - 2013)
Newton, MA (US) (2021)
Needham, MA (US) (2012 - 2023)

Company Filing History:

56 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

PRMT5 Inhibitors

STING Agonists

IRAK4 Inhibitors

Cyclic Di-Nucleotide Compounds

Spleen Tyrosine Kinase

Aza-Benzothiophene Compounds

Pyrazolopyrimidine Inhibitors

Thiazole-Substituted Aminoheteroaryls

Pyrrolotriazine Inhibitors

Indazole Inhibitors

Purine Inhibitors

Triazolyl Derivatives

59 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12595262 - PRMT5 inhibitors (2026-04-07),

2. 12595248 - PRMT5 inhibitors (2026-04-07),

3. 12583871 - PRMT5 inhibitors (2026-03-24),

4. 12441730 - PRMT5 inhibitors (2025-10-14),

5. 11702430 - Aza-benzothiophene compounds as STING agonists (2023-07-18),

6. 11453697 - Cyclic di-nucleotide compounds as sting agonists (2022-09-27),

7. 11311528 - Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors (2022-04-26),

8. 11098059 - PRMT5 inhibitors (2021-08-24),

9. 10947234 - PRMT5 inhibitors (2021-03-16),

10. 10793557 - Sting agonist compounds (2020-10-06),

11. 10766919 - Cyclic di-nucleotide compounds as sting agonists (2020-09-08),

12. 10759825 - Cyclic di-nucleotide compounds as STING agonists (2020-09-01),

13. 10738074 - Cyclic di-nucleotide compounds as STING agonists (2020-08-11),

14. 10730849 - Benzo[b]thiophene compounds as STING agonists (2020-08-04),

15. 10703738 - Benzo[b]thiophene compounds as STING agonists (2020-07-07),

Title: The Innovative Journey of Michael D Altman

Introduction: Michael D Altman, a pioneering inventor based in Needham, MA (US), has made significant contributions to the field of technology through his inventive spirit and dedication to innovation.

Latest Patents: Michael D Altman holds several patents in various technological domains, showcasing his versatility and creativity in inventing novel solutions to complex problems.

Career Highlights: Throughout his illustrious career, Michael D Altman has been at the forefront of technological advancements, leading groundbreaking projects and pushing the boundaries of innovation. His passion for creating cutting-edge solutions has earned him recognition as a visionary inventor.

Collaborations: Michael D Altman has collaborated with leading tech companies, research institutions, and universities to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of his projects.

Conclusion: In conclusion, Michael D Altman's innovative spirit, coupled with his relentless drive to push the boundaries of technology, has established him as a prominent figure in the world of inventions. His contributions have not only transformed industries but have also inspired future generations of inventors to pursue their creative visions.